Corvus Pharmaceuticals (CRVS) Assets (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Assets of $253.2 million for Q1 2026, up 325.98% year-over-year from $59.4 million in Q1 2025, and up 256.02% quarter-over-quarter from $71.1 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Assets (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Assets history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.
- In Q1 2026, Assets rose 325.98% year-over-year to $253.2 million; the TTM figure through Mar 2026 stood at $253.2 million (up 325.98% YoY), while the FY2025 annual figure was $71.1 million, up 3.21% from the prior year.
- Assets for Q1 2026 stood at $253.2 million, up from $71.1 million in the prior quarter.
- The five-year high for Assets was $253.2 million in Q1 2026, with the low at $40.1 million in Q1 2024.
- The 5-year median for Assets is $68.2 million (2022), against an average of $79.0 million.
- The sharpest annual moves came in 2023 and 2026: Assets slumped 42.54% in 2023, then soared 325.98% in 2026.
- Corvus Pharmaceuticals' Assets stood at $68.2 million in 2022, then tumbled by 33.25% to $45.6 million in 2023, then jumped by 51.27% to $68.9 million in 2024, then climbed by 3.21% to $71.1 million in 2025, then soared by 256.02% to $253.2 million in 2026.
- Business Quant data shows CRVS's Assets at $253.2 million in Q1 2026, $71.1 million in Q4 2025, and $80.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 239.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.27 Mn |
| Mar 31, 2026 | 253.20 Mn |
| Dec 31, 2025 | 71.12 Mn |
| Sep 30, 2025 | 80.47 Mn |
| Jun 30, 2025 | 89.46 Mn |
| Mar 31, 2025 | 59.44 Mn |
| Dec 31, 2024 | 68.91 Mn |
| Sep 30, 2024 | 58.82 Mn |
| Jun 30, 2024 | 64.56 Mn |
| Mar 31, 2024 | 40.08 Mn |
| Dec 31, 2023 | 45.55 Mn |
| Sep 30, 2023 | 51.94 Mn |
| Jun 30, 2023 | 58.04 Mn |
| Mar 31, 2023 | 58.20 Mn |
| Dec 31, 2022 | 68.24 Mn |
| Sep 30, 2022 | 80.35 Mn |
| Jun 30, 2022 | 92.54 Mn |
| Mar 31, 2022 | 101.29 Mn |
| Dec 31, 2021 | 109.46 Mn |
| Sep 30, 2021 | 119.32 Mn |